Savara, Inc. stock is up 22.58% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 December’s closed higher than November. 100% of analysts rate it a buy.
Savara Inc. focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor. The company is headquartered in Austin, Texas.